Resistin

Resistin was discovered in 2001 and identified as a hormone produced by adipose tissue, with a role in promoting insulin resistance. Specifically, elevated resistin levels appear to interfere with the action of insulin on adipose cells. Subsequent studies noted a link between resistin and activation of pro-inflammatory cytokines. Resistin is a cysteine-rich, secreted peptide hormone characterized by a unique multimeric structure. Each resistin monomer consists of a C-terminal, disulfide-rich beta-sandwich "head" domain and an N-terminal alpha-helical "tail" segment. The head domain adopts a six-stranded jelly-roll topology, forming two three-stranded antiparallel beta-sheets, while the tail segments associate to create three-stranded coiled coils. These monomers assemble into trimers, and further interchain disulfide linkages mediate the formation of tail-to-tail hexamers, resulting in a multimeric assembly stabilized by disulfide bonds. In circulation, resistin exists in multiple assembly states, including high-molecular-mass hexamers and lower-molecular-mass trimers, with the oligomeric form in humans showing greater proinflammatory activity. This structural organization is highly conserved within the resistin-like molecule family of peptide hormones. == Function ==

Resistin is a multifunctional hormone that plays critical roles in metabolic regulation, inflammation, and innate immunity. In humans, resistin is primarily expressed by immune cells such as monocytes and macrophages, where it acts as a pro-inflammatory cytokine by stimulating the production of cytokines including IL-6, IL-1β, and TNF-α through activation of signaling pathways involving the TLR4 and CAP1 receptors. Beyond its pro-inflammatory effects, resistin also demonstrates direct antimicrobial activity by damaging bacterial membranes, and it modulates immune responses by recruiting and activating immune cells, promoting chemokine production, and enhancing the formation of neutrophil extracellular traps (NETs). Notably, resistin exhibits bidirectional immunomodulatory properties: while it can amplify inflammation in response to certain stimuli, it can also attenuate excessive inflammatory responses triggered by bacterial products such as lipopolysaccharide (LPS), potentially by competing for TLR4 binding or directly neutralizing LPS. This dual functionality positions resistin as an important regulator of host defense and inflammatory balance in both health and disease. == Clinical significance ==

Obesity and insulin resistance Much of what is hypothesized about a resistin role in energy metabolism and T2DM can be derived from studies showing strong correlations between resistin and obesity, the premise being that serum resistin levels increase with increased adiposity. Conversely, serum resistin levels to decline with decreased adiposity following medical treatment. Specifically, central obesity (waistline adipose tissue) is the region of adipose tissue that contributes most to rising levels of serum resistin. This is significant, considering the link between central obesity and insulin resistance, two marked peculiarities of T2DM. On the other hand, at least one study has found no correlation between resistin levels and obesity or insulin resistance in humans, so the resistin–insulin resistance connection may be regarded as somewhat unsettled. Although resistin levels increase with obesity, it is questioned whether this increase is responsible for the insulin resistance associated with increased adiposity. Several reports have shown a positive correlation between resistin levels and insulin resistance. This is supported by reports of correlation between resistin levels and subjects with T2DM. If resistin contributes to the pathogenesis of insulin resistance in T2DM, then designing drugs to promote decreased serum resistin in T2DM subjects may deliver therapeutic benefits. Resistin can increase levels of circulating low-density lipoprotein (LDL) and accelerates LDL accumulation in arteries, increasing risk of heart disease has an adverse impact on the efficacy of statins, the primary drug used to reduce cholesterol in fighting of cardiovascular disease. In the liver, resistin increases LDL production and degrades LDL receptors, impairing the ability to process LDL. Inflammation Beyond its role as a hormone, resistin also contributes to inflammation. Interleukin-12 (IL-12) and tumor necrosis factor-α (TNF-α) are up-regulated by resistin in an NF-κB-mediated fashion. Likewise, in vitro studies show Toll-like receptor 2 expression is increased by resistin. Resistin itself can be upregulated by interleukins and also by microbial antigens such as lipopolysaccharide, which are recognized by leukocytes. Together, these findings suggest resistin may be a link in the well-known association between inflammation and insulin resistance. Resistin also seems to be a marker of inflammation in semen. Resistin levels correlate positively with those of proinflammatory mediators such as interleukin-6 (IL-6), elastase and tumor necrosis factor-α (TNF-α) in seminal plasma. During inflammation, the concentrations of cytokines and ROS increase, and this may have a deleterious effect on the male reproductive function. One study showed that there was a negative correlation between the concentrations of seminal resistin and spermatic motility and vitality. == References ==